Journal article
Macrophage-Engineered Vesicles for Therapeutic Delivery and Bidirectional Reprogramming of Immune Cell Polarization
ACS omega, Vol.6(5), pp.3847-3857
02/09/2021
DOI: 10.1021/acsomega.0c05632
PMCID: PMC7876833
PMID: 33585763
Abstract
Macrophages, one of the most important phagocytic cells of the immune system, are highly plastic and are known to exhibit diverse roles under different pathological conditions. The ability to repolarize macrophages from pro-inflammatory (M1) to anti-inflammatory (M2) or vice versa offers a promising therapeutic approach for treating various diseases such as traumatic injury and cancer. Herein, it is demonstrated that macrophage-engineered vesicles (MEVs) generated by disruption of macrophage cellular membranes can be used as nanocarriers capable of reprogramming macrophages and microglia toward either pro- or anti-inflammatory phenotypes. MEVs can be produced at high yields and easily loaded with diagnostic molecules or chemotherapeutics and delivered to both macrophages and cancer cells in vitro and in vivo. Overall, MEVs show promise as potential delivery vehicles for both therapeutics and their ability to controllably modulate macrophage/microglia inflammatory phenotypes.
Details
- Title: Subtitle
- Macrophage-Engineered Vesicles for Therapeutic Delivery and Bidirectional Reprogramming of Immune Cell Polarization
- Creators
- Khaga R. Neupane - University of KentuckyJ. Robert McCorkle - University of KentuckyTimothy J. Kopper - University of KentuckyJourdan E. Lakes - University of KentuckySurya P. Aryal - University of KentuckyMasud Abdullah - University of KentuckyAaron A. Snell - University of KentuckyJohn C. Gensel - University of KentuckyJill Kolesar - University of KentuckyChristopher Richards - University of Kentucky
- Resource Type
- Journal article
- Publication Details
- ACS omega, Vol.6(5), pp.3847-3857
- Publisher
- Amer Chemical Soc
- DOI
- 10.1021/acsomega.0c05632
- PMID
- 33585763
- PMCID
- PMC7876833
- ISSN
- 2470-1343
- eISSN
- 2470-1343
- Number of pages
- 11
- Grant note
- PON2 728 2000002500 / Kentucky Pediatric Cancer Research Trust Fund
- Language
- English
- Date published
- 02/09/2021
- Academic Unit
- Pharmacy; Pharmaceutical Sciences and Experimental Therapeutics
- Record Identifier
- 9984696548302771
Metrics
5 Record Views